Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Figure 5 Tumor response evaluation.
A: Waterfall plot showing the maximum percentage change in target lesion size for each patient according to RECIST 1.1 criteria; B: Bar chart comparing objective response rate and disease control rate between the two groups. ORR: Objective response rate; DCR: Disease control rate; PD: Progressive disease; PR: Partial response; SD: Stable disease.
- Citation: Zhang C, Wu SH, Jin L, Lu L, Li J, Jin S. Propensity score-based real-world study of immune checkpoint inhibitor combination therapy in microsatellite stable/proficient mismatch repair metastatic colorectal cancer. World J Gastrointest Oncol 2026; 18(11): 124022
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/124022.htm
- DOI: https://dx.doi.org/10.4251/wjgo.124022